Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

ACET

Phase 1

ADI-270

Renal Cell Carcinoma

H1 2025

8/13/24- IND cleared. 11/18/24- Opened enrollment with preliminary Ph1 data in H1 2025. 12/19/24- First patient dosed. Poster presentation at SITC '25 Spring Meeting on Mar 13, 2025.

Data readout

VALN

Phase 1

VLA1601

Zika vaccine (2nd generation)

H1 2025

3/26/24 Initiates Ph1 trial. Topline data in H1 2025.

Data readout

XNCR

Phase 1

XmAb942

Inflammatory bowel disease (IBD)

H1 2025

10/10/24 Present preclinical data at UEG Week. 11/4/24 Doses first subject. 2/27/25- SAD data in H1 2025 & MAD data in H2 2025.

Data readout

ACRS

Phase 2a

ATI-2138 (ITK/JAK3 inhibitor)

Moderate to severe atopic dermatitis

H1 2025

9/17/24- First patient dosed in Ph2a. Topline data in H1 2025.

Data readout

ALXO

Phase 1

Evorpacept + enfortumab vedotin-ejfv/PADCEV®

Urothelial cancer (UC)

H1 2025

ASPEN-07 study. 2/16/23- First patient dosed. 6/2/24- Presented poster at ASCO '24. Updated data in H1 2025.

Data readout

EGRX

Phase 2/3

Intravenous Amisulpride

Postoperative Nausea and Vomiting (PONV) in Pediatric patients

H1 2025

Present Ph2/3 trial in progress at SAMBA '24. Preliminary results in H1 2025.

Data readout

ANAB

Phase 2b

Rosnilimab (ANB030) (PD-1 agonist)

Rheumatoid arthritis

Q2 2025

08/2023- Initiated trial. 2/12/25- Reported topline 12wk data, met primary & secondary endpoints. Full wk 28 and additional translational RA data in Q2 2025

Additional Data readout

APRE

Phase 1/2a

ATRN-119

Solid Tumor/s

H1 2025

ABOYA-119 trial (Ph1/2a) . 5/28/24- SRC endorsed dosing at 800mg once daily. 12/11/24- First patient dosed at Dose Level 7 (550 mg) twice daily dosing. Dose escalation continues with Ph1 data in H1 2025.

Data Readout

GRTS

Phase 2/3

GRANITE

Solid tumors, MSS-CRC (Microsatallite Stable Colorectal Cancer), GEA (Gastroesophageal cancer)

H2 2025

GRANITE. 4/1/24- Prelim PFS & ctDNA data. 9/30/24- Reported interim Ph2 data. 10/10/24- Filed voluntary petition under chapter 11 of US Bankruptcy Code. 11/11/24- Updated interim Ph2 data. OS mature data in H2 2025.

Data readout

ONCY

Phase 1/2

Pelareorep + modified FOLFIRINOX

Metastatic pancreatic ductal adenocarcinoma (PDAC)

H1 2025

PanCAN supported trial. GOBLET (mFOLFIRINOX cohort) Initiate Ph1/2 combo study in H1 2024. Poster presentation at ASCO '24. 6/20/24- Dosed first patient. 10/4/24 Cohort 5 Safety run-in update in H1 '25 & Initial efficacy results in H2 2025. 12/3/24- Completed initial safety phase enrollment. 1/15/25- Regulatory approval of continuation of patient enrollment into Cohort 5.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20